Etude de phase 2, évaluant l’efficacité d’un traitement par immunothérapie, chez des patients ayant un carcinome non résécable non traité avec des instabilités des microsatellites et une défaillance du système de réparation de l'ADN (MSI-dMMR) ou un cancer gastrique EBV+

Essai clinique

Type : Académique
Statut : Ouvert
Phase : II
Date d'ouverture : 18/10/2021
Date clôture : 31/10/2026
Promoteur : Centre Leon Berard
Progression du cancer: Loco-régional
Résumé :

This trial is a multicenter, 4-cohort, prospective, Phase II trial conducted in patients with untreated resectable MSI/dMMR carcinomas or EBV+ gastric cancer and aiming to evaluate the safety and the efficacy of ICI (immune checkpoint inhibitor) as neoadjuvant treatment in these patients.

We hypothesize that immune checkpoint inhibitors (ICPi) will benefit to MSI/dMMR tumors from the early stages, whatever their anatomical origin. We assume that this neoadjuvant treatment would improve the response rate, providing even high rate of pathological complete responses and prolong patients survival.

We anticipated endometrial, colorectal and gastric cancers to be the most frequent recruited and constructed our statistical hypothesis with results in those 3 cancers. However patients with other localized MSI/dMMR tumors could be included.

Domaines/spécialités :
  • Cancers digestifs
    • Œsophage
    • Estomac
    • Colon
    • Rectum
    • Foie –Voie biliaire
    • Pancréas
    • Carcinose péritionéale
    • Autres cancers digestifs
  • Cancers gynécologiques
    • Endomètre
Pathologies :
  • Tumeur maligne de l'oesophage - Cim10 : C15
  • Tumeur maligne de l'estomac - Cim10 : C16
  • Tumeur maligne du côlon - Cim10 : C18
  • Tumeur maligne du rectum - Cim10 : C20
  • Tumeur maligne du pancréas - Cim10 : C25
  • Tumeur maligne du rétropéritoine et du péritoine - Cim10 : C48
  • Tumeur maligne du duodénum - Cim10 : C170
  • Tumeur maligne du jéjunum - Cim10 : C171
  • Tumeur maligne de l'iléon - Cim10 : C172
  • Tumeur maligne des voies biliaires, sans précision - Cim10 : C249
  • Tumeur maligne de l'endomètre - Cim10 : C541
Liens externes :

Critères de population

Sexe : Homme et femme
Age minimum : 18 ans
Critères d’inclusion :

I1. Age ≥ 18 years on the day of signing informed consent.

I2. Histologically proven localized non-metastatic tumor included in one of the 4 cohorts:

  • Colorectal Cancer (cT3/T4 N0 M0 ou cT N+ M0 on thoraco-abdomino-pelvic TAP CT-scan and echo-endoscopy) OR
  • Oesogastric (gastric, gastro-oesophageal or oesophageal) cancer (cT2 to cT4 N M0 on TAP CT-scan and echo-endoscopy) OR
  • Endometrial carcinoma (stage III) OR
  • Other tumor types (cT2 to cT4 N M0 on TAP CT-scan and echo-endoscopy): biliary tract or pancreas adenocarcinoma, small bowel adenocarcinoma (duodenum, jejunum, ileum), peritoneum adenocarcinoma.

I3. MSI/dMMR established by immunohistochemistry (IHC) [MMR protein expression] and polymerase chain reaction (PCR) [both techniques are required] and validated by coordinator's team.

MMR and/or MSI tumors will be assessed using IHC with four antibodies (anti-MLH1, anti-MSH2, anti-MSH6 and anti-PMS2) and PCR (pentaplex panel is recommended: BAT-25, BAT-26, NR-21, NR-24, and NR-27) prior to screening. Loss of MLH1 and PMS2 / or MSH2 and MSH6 / or MSH6 alone / or PMS2 alone protein staining by IHC indicates dMMR, and tumor with ≥ 2 unstable markers among 5 microsatellite markers analyzed on PCR (BAT25, BAT26, NR21, NR24, and NR27) proves MSI/dMMR.

OR EBV-positive gastric cancers. EBV positivity will be assessed by EBER (EBV-encoded small RNAs) in situ hybridization (ISH) (EBER-PNA EnVision flex probe (Dako)). The intensity of staining (weak, moderate or intense) and the percentage of positive cells will be recorded. Cases showing nuclear staining in at least 5% of tumor cells will be considered positive for EBV infection.

I4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 1 within 7 days prior to the inclusion.

I5. Adequate bone-marrow, hepatic, and renal functions, within 10 days prior to the start of study treatment with:

  • Hemoglobin ≥ 9 g/dl or ≥ 5.6 mmol/l, neutrophils ≥ 1.0 x 10^9/l, platelets ≥ 100 x 10^9/l,
  • Creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 ml/min/1.73m² using either MDRD or CKD-EPI formula,
  • AST and ALT ≤ 3 x ULN, total bilirubin ≤ 1.5 ULN (or direct bilirubin ≤ ULN for patients with total bilirubin >1.5 × ULN),
  • International normalized ratio (INR) OR prothrombin time (PT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or activated partial thromboplastin time (aPTT) is within therapeutic range of intended use of anticoagulants.

I6. Covered by a medical/health insurance.

I7. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

I8. Patients of childbearing potential accepting to use effective contraceptive measures or abstain from heterosexual activity, for the course of the study through 4 months after the last dose of pembrolizumab MK-3475 adjuvant treatment or 6 months after adjuvant chemotherapy or being surgically sterile. Refer to Appendix 1 for approved methods of contraception.

I9. Signed and dated IRB/IE approved informed consent form.

Critères d’exclusion :

E1. MSS/pMMR tumors.

E2. Metastatic disease (stage IV).

E3. HIV positive with CD4 count under 400 cells/mm3.

E4. Active Hepatitis B virus (HBV), defined by a positive hepatitis B surface antigen [HBsAg] test prior to inclusion, or Hepatitis C virus (HCV) infection.

E5. Active systemic autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg. thyroxine, insulin) is not considered a form of systemic treatment and is allowed.

E6. Interstitial lung disease.

E7. Prior (non-infectious) pneumonitis requiring systemic corticosteroid therapy or current pneumonitis.

E8. History of severe hypersensitivity to another monoclonal antibody.

E9. Receiving immunosuppressive therapy or having received corticosteroids (in dosing exceeding 10 mg daily of prednisone equivalent) within the last 2 months before inclusion.

E10. Active infections.

E11. Radiotherapy within the 2 weeks before inclusion. Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease

E12. Live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.

E13. Known history of active TB (Bacillus Tuberculosis).

E14. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.

E15. Pregnant or breastfeeding woman or patient expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 4 months after the last dose of study treatment.

E16. Patient requiring tutorship or curatorship.

E17. Ongoing anti-cancer treatment for another cancer (to be discussed with the coordinator in case of hormone therapy).

Centre d'investigation

En cours
Nom : Centre Georges François Leclerc - CGFL
Ville : DIJON (21)
Prénom : François
Téléphone : Non disponible
Email :
Prénom : Justine
Téléphone : 03 80 73 77 52
Email :

Référentiels Oncologik

  • Estomac